Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0068

Scientific exchange · Dr. Javier Ivanova

10 Aug 2026 · Virtual · Dr. Javier Ivanova, Johns Hopkins · MSL James Whitfield · Vantrexa

ReviewedManualENG-0068MI request

Capture insight from this engagement

Location: Johns Hopkins
Therapeutic area: Oncology
Country: United States
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Vantrexa (vantrelimab)

Topics discussed

Chemotherapy-free first line

Scientific content used

PD-L1 testing pathway infographic

Questions raised

No questions recorded.

Notes

Scientific exchange with radiation oncologist at Johns Hopkins. Discussed chemotherapy-free first line.

Insights captured (1)

Capture insight

INS-0076Medium
Chemotherapy-free first line
Chemotherapy-free first line: request for data reported by radiation oncologist (US).
Action in progress

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Invite to advisory board

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 5
Strategic relevance: 2
Depth of exchange: 4
Actionability: 2

Data lineage

Source system: Manual
Sync: Entered manually in Hub
System of record: Hub
Record id: ENG-0068

Audit history (0)

All create, update and approval events for this record

No audit events in sample data